NewsMV
ResMed (NYSE:RMD) shares have underperformed the broader market over the past six months, posting a 2.7% decline while the S&P 500 index gained 15.9%.
The stock currently trades at $218.94 per share, a level that reflects recent weakness despite the company's long-term operational track record.
For investors holding or considering the position, this divergence highlights a tension between the company's historical execution and its immediate outlook.
The company, which was founded in 1989 to address sleep apnea, develops cloud-connected medical devices and software for treating respiratory disorders in home and clinical settings.
Keep reading